Abstract
Abstract: Neonatal hypoxic-ischemic encephalopathy (HIE) is one of the main causes of brain injury and death in infants. This article aimed to investigate the effects of mild hypothermia therapy on neuroprotection and cytokine levels in neonates with HIE. 132 children with HIE in the Northwest Women's and Children's Hospital between January 2022 and April 2023 were enrolled as the study subjects, and they were grouped by the method of random number table, controls using conventional treatment intervention, mild hypothermia group adopting mild hypothermia therapy based on conventional treatment. The levels of cytokines and neonatal behavioral neurological assessment (NBNA) were compared before and following remedy. As against controls, in mild hypothermia therapy-treated subjects, the levels of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and superoxide dismutase (SOD) were clearly raised; the levels of malondialdehyde (MDA), interleukin (IL-18), and Caspase-3 were clearly decreased, and the NBNA score of mild hypothermia therapy-treated subjects was clearly raised; the recovery time of neurological function was clearly shortened (all P <0.05). Mild hypothermia therapy has an obvious neuroprotective outcome on neonates with HIE, possibly by regulating the levels of cytokines.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.